PL EN


Preferences help
enabled [disable] Abstract
Number of results
2014 | 61 | 2 | 325-331
Article title

Identification of serum proteome components associated with progression of non-small cell lung cancer

Content
Title variants
Languages of publication
EN
Abstracts
EN
The aim of the present study was to perform comparative analysis of serum from patients with different stages of non-small cell lung cancer (NSCLC) using the three complementary proteomic approaches to identify proteome components associated with the progression of cancer. Serum samples were collected before any treatment from 200 patients with NSCLC, including 103 early stage, 64 locally advanced and 33 metastatic cancer samples, and from 200 donors without malignancy. The low-molecular-weight fraction of serum proteome was MALDI-profiled in all samples. Serum proteins were characterized using 2D-PAGE and LC-MS/MS approaches in a representative group of 30 donors. Several significant differences were detected between serum samples collected from patients with early stage cancer and patients with locally advanced cancer, as well as between patients with metastatic cancer and patients with local disease. Of note, serum components discriminating samples from early stage cancer and healthy persons were also detected. In general, about 70 differentiating serum proteins were identified, including inflammatory and acute phase proteins already reported to be associated with the progression of lung cancer (serum amyloid A or haptoglobin). Several differentiating proteins, including apolipoprotein H or apolipoprotein A1, were not previously associated with NSCLC. No significant differences in patterns of serum proteome components were detected between patients with adenocarcinoma and squamous cell carcinoma. In conclusion, we identified the biomarker candidates with potential importance for molecular proteomic staging of NSCLC. Additionally, several serum proteome components revealed their potential applicability in early detection of the lung cancer.
Publisher

Year
Volume
61
Issue
2
Pages
325-331
Physical description
Dates
published
2014
received
2013-12-20
revised
2014-04-01
accepted
2014-04-17
(unknown)
2014-05-29
Contributors
  • Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
author
  • Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
  • Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
  • Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
  • Polish Academy of Science, Institute of Bioorganic Chemistry, Poznań, Poland
  • Polish Academy of Science, Institute of Bioorganic Chemistry, Poznań, Poland
  • Silesian University of Technology, Gliwice, Poland
  • Silesian University of Technology, Gliwice, Poland
  • Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
author
  • Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
  • Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
  • Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
  • Medical University of Gdańsk, Gdańsk, Poland
author
  • Medical University of Gdańsk, Gdańsk, Poland
author
  • Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
References
  • Beecken WD, Ringel EM, Babica J, Oppermann E, Jonas D, Blaheta RA (2010) Plasmin-clipped beta(2)-glycoprotein-I inhibits endothelial cell growth by down-regulating cyclin A, B and D1 and up-regulating p21 and p27. Cancer Lett 296: 160-167.
  • Bharti A, Ma PC, Maulik G, Singh R, Khan E, Skarin AT, Salgia R (2004) Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res 24: 1031-1038.
  • Carbone DP, Ding K, Roder H, Grigorieva J, Roder J, Tsao MS, Seymour L, Shepherd FA (2012) Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. J Thorac Oncol 7: 1653-1660.
  • Cho WC, Yip TT, Cheng WW, Au JS (2010) Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Brit J Cancer 102: 1731-1735.
  • Coche E, Lonneux M, Geets X (2010) Lung cancer: Morphological and functional approach to screening, staging and treatment planning. Future Oncol 6: 367-380.
  • Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, Kiernan I, O'Byrne KJ, Kennedy MJ, Lynch V, Clynes M (2012) Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer 131: 911-923.
  • Han KQ, Huang G, Gao CF, Wang XL, Ma B, Sun LQ, Wei ZJ (2008) Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Am J Clin Oncol 31: 133-139.
  • Hoagland LF, Campa MJ, Gottlin EB, Herndon JE, Patz EF (2007) Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer 110: 2260-2268.
  • Jing X, Piao YF, Liu Y, Gao PJ (2010) Beta2-GPI: a novel factor in the development of hepatocellular carcinoma. J Cancer Res Clin Oncol 136: 1671-1680.
  • Liotta LA, Ferrari M, Petricoin EF (2003) Clinical proteomics: written in blood. Nature 425: 905.
  • Lu X, Yang X, Zhang Z, Wang D (2010) Meta-analysis of serum tumor markers in lung cancer. Chin J Lung Cancer 13: 1136-1140.
  • Lustgarten JL, Kimmel C, Ryberg H, Hogan W (2008) EPO-KB: a searchable knowledge base of biomarker to protein links. Bioinformatics 24: 1418-1419.
  • Malle E, Sodin-Semrl S, Kovacevic A (2009) Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 66: 9-26.
  • Manenti G, Cicciò C, Squillaci E, Strigari L, Calabria F, Danieli R, Schillaci O, Simonetti G (2012) Role of combined DWIBS/3D-CE-T1w whole-body MRI in tumor staging: Comparison with PET-CT. Eur J Radiol 81: 1917-1925.
  • Mi H, Thomas P (2009) PANTHER pathway: an ontology-based pathway database coupled with data analysis tools. Methods Mol Biol 563: 123-140.
  • Ocak S, Chaurand P, Massion PP (2009) Mass spectrometry-based proteomic profiling of lung cancer. Proc Am Thorac Soc 6: 159-170.
  • Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE 2nd (2007) Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 25: 5578-5583.
  • Pennell D (2010) An overview of molecular markers in Lung Cancer. Available at:
  • Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27: 3437-3444.
  • Pietrowska M, Marczak L, Polanska J, Behrendt K, Nowicka E, Walaszczyk A, Chmura A, Deja R, Stobiecki M, Polanski A, Tarnawski R, Widlak P. (2009) Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer. J Transl Med 7: 60.
  • Pietrowska M, Polańska J, Suwiński R, Wideł M, Rutkowski T, Marczyk M, Domińczyk I, Ponge L, Marczak L, Polański A, Widłak P (2012) Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: association with tumor progression. Int J Oncol 40: 148-156.
  • Sobin LH, Gospodarowicz MK, Wittekind CH (2009) TNM Classification of Malignant Tumors. 7th ed. Wiley-Blackwell.
  • Sos ML, Thomas RK (2012) Genetic insight and therapeutic targets in squamous-cell lung cancer. Oncogene 31: 4811-4814.
  • Subramanian J, Simon R (2010) Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 102: 464-474.
  • Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA Jr, Carbone DP (2007) Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 99: 838-846.
  • Toyooka S, Mitsudomi T, Soh J, Aokage K, Yamane M, Oto T, Kiura K, Miyoshi S (2011) Molecular oncology of lung cancer. Gen Thorac Cardiovasc Surg 59: 527-537.
  • van Loon J, van Baardwijk A, Boersma L, Ollers M, Lambin P, De Ruysscher D (2011) Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer. Cancer Treat Rev 37: 331-343.
  • Yanagisawa K, Tomida S, Shimada Y, Yatabe Y, Mitsudomi T, Takahashi T (2007) A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst 99: 858-867.
  • Yildiz PB, Shyr Y, Rahman JS, Wardwell NR, Zimmerman LJ, Shakhtour B, Gray WH, Chen S, Li M, Roder H, Liebler DC, Bigbee WL, Siegfried JM, Weissfeld JL, Gonzalez AL, Ninan M, Johnson DH, Carbone DP, Caprioli RM, Massion PP (2007) Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol 2: 893-901.
  • Zamanian-Daryoush M, Lindner D, Tallant TC, Wang Z, Buffa J, Klipfell E, Parker Y, Hatala D, Parsons-Wingerter P, Rayman P, Yusufishaq MS, Fisher EA, Smith JD, Finke J, DiDonato JA, Hazen SL (2013) The cardioprotective protein ApoA1 promotes potent anti-tumorigenic effects. J Biol Chem 288: 21237-21252.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv61p325kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.